March 2, 2023
We are thrilled to announce a groundbreaking, first in class treatment for Geographic Atrophy –SYFOVRE™ (pegcetacoplan injection) — and incredibly proud that our own Dr. Howard Fine was the first physician in New Jersey to treat patients with it yesterday!
Howard F. Fine, M.D., Retina Specialist and Vitreoretinal Surgeon with NJRetina stated: “I am delighted we are now able to offer treatment to patients with geographic atrophy (GA) from dry age-related macular degeneration (AMD). This blinding eye disease is a large public health problem, affecting about 1 million Americans. NJRetina and I were involved in the clinical trials which showed significant reductions in disease progression and will be a gamechanger for our patients.”
Steven Madreperla, M.D., Ph.D., President and CEO of PRISM Vision Group added: “This is truly a great day. As a Retina Surgeon, I am thrilled that a treatment is now available for the many patients we take care of with geographic atrophy. As the President and CEO of PRISM Vision Group, I am incredibly proud of our clinicians to be the first in the nation to utilize this treatment as well as all those on our team that led and participated in the clinical trials that led to SYFOVRE™’s FDA approval. Our doctor’s dedication to the progression of the science of medicine through our robust clinical trials program is one of the many things that sets PRISM apart.”
To find out more about how we may be able to assist your previously untreatable patients with GA, please contact us at www.njretina.com or 855-NJRETINA.
